Platelet-rich plasma effective remedy for dry eye

Article

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Jorge Alio and colleagues from the Instituto Oftalmologico de Alicante and the Universidad Migul Hernandez, Alicante, Spain, treated 18 consecutive dry eye patients with topical PRP. The researchers were looking for the disappearance of subjective symptoms, increases in best corrected visual acuity (BCVA), tear meniscus, tear break-up time and decreases in inflammation and fluorescein staining. Improvements in impression cytology were also measured.

At one-month follow-up, 89% of subjects demonstrated a significant improvement in symptoms and 28% improved by at least one line of BCVA. A significant improvement in lachrymal meniscus and conjunctival hyperaemia, and a decrease or disappearance of corneal fluorescein staining was observed. Meanwhile, impression cytology revealed a significant increase in conjunctival goblet cells.

The authors of the study conclude that autologous PRP is a very effective treatment for severe dry eye symptoms.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.